PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: StockInterview.com

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Sernova President Believes Diabetics Could Forego Anti-Rejection Drugs with New Therapy - Sernova Corp President Justin Leushner believes his company’s current cell replacement therapy research could help diabetics avoid a lifetime of anti-rejection drug use
Sernova President Believes Diabetics Could Forego Anti-Rejection Drugs with New Therapy

 

NewswireToday - /newswire/ - Sarasota, FL, United States, 2006/12/13 - Sernova Corp President Justin Leushner believes his company’s current cell replacement therapy research could help diabetics avoid a lifetime of anti-rejection drug use.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Sernova Corp (TSX-V: SVA) President Justin Leushner told StockInterview.com in a posted audio interview, “We believe we will be able to replace (a diabetic’s) cells without a lifetime use of anti-rejection drugs.” Leushner also said that the company’s islet transplant therapy could help some nine million diabetics in America avoid daily insulin injections. Diabetes is the fifth leading cause of death in the United States, sometimes leading to amputations and blindness.

Asked about the use of pig islets in cell replacement therapy, Leushner responded, “Pig insulin is virtually identical to human insulin.” He pointed out that pig insulin has been used by diabetics for insulin injections.

Leushner praised the Edmonton Protocol islet transplant therapy as a ‘proof of concept’ and said that there was additional ‘proof of concept’ research validating the research his company was currently engaged in. Questioned about the recent criticism of the Edmonton Protocol, Leushner told StockInterview.com, “We believe our technology will be effective for the long term.”

About Stockinterview.com

Stockinterview.com is an online news service, which provides investigative reporting, editorial, analysis and provocative commentary of the nuclear fuel cycle, uranium mining, nuclear power, the environment and the natural resource industry. From time to time, StockInterview.com editors cover biotechnology and other sectors. StockInterview.com is best known for its 304-page trade softcover edition of “Investing in the Great Uranium Bull Market,” please visit bookstore link below.

About Sernova Corp

Sernova Corp (TSX: SVA) is a biotechnology research and development company. The company’s lead project is research into reversing insulin dependent diabetes through transplanted pig islet and Sertoli cells. SVA shares closed down two cents on Monday at C$0.41/share on more than 15,000 shares traded. Company’s website is sernovacorp.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: StockInterview.com

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Sernova President Believes Diabetics Could Forego Anti-Rejection Drugs with New Therapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Julie Ickes 
941-929-1640 editor[.]stockinterview.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any StockInterview.com securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From StockInterview.com / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)